Bayer Logo Bayer Logo Bayer Logo Bayer Logo


Get them to where they need to be

Kovaltry is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency) for adults, adolescents and children of all ages.


Confidence in Kovaltry in clinical and real-world settings

Kovaltry is backed by Leopold studies that consisted of 193 PTPs (143 adults/adolescents and 51 pediatrics)1,2,3

Launched in 2016, Kovaltry has accumulated 13,753 patient-years of exposure* to 31 August 20194

Kovaltry SmPC

PTP, previously treated patient

*Patient years of exposure = International Units sold/annual dose per patient


  • Saxena K, Lalezari S, Oldenburg J, et al. Efficacy and safety of BAY 81-8973, a full-length recombinant factor VIII: results from the LEOPOLD I trial.Haemophilia. 2016;22(5): 706-712. Return to content
  • Kavakli K, Yang R, Rusen L, et al. Prophylaxis vs. on-demand treatment with BAY 81-8973, a full-length plasma protein-free recombinant factor VIII product: results from a randomized trial (LEOPOLD II). J Thromb Haemost. 2015;13(3):360-36. Return to content
  • Ljung R, Kenet G, Mancuso M, et al. BAY 81-8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial Haemophilia. 2016;22(3):354-60. Return to content
  • Bayer Data on File. August 2019. Return to content